FDA ApprovedUnited States
First FDA-Approved Gene Therapy Sheets for RDEB Wounds
Zevaskyn (prademagene zamikeracel) — gene-modified cellular sheets surgically applied to treat wounds in recessive dystrophic epidermolysis bullosa
FDA approval on 28 April 2025 for Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets — an autologous cell sheet-based gene therapy for…
This is for people living with recessive dystrophic epidermolysis bullosa — and the caregivers who help them — who have chronic open wounds and may be…